FDA Grants Pomalidomide Breakthrough Designation in Kaposi Sarcoma

May 13, 2019 – The FDA has granted a breakthrough therapy designation to pomalidomide for use as a treatment for patients with HIV-positive Kaposi sarcoma who have received prior chemotherapy, as well as patients with HIV-negative Kaposi sarcoma. The designation was based on results of a phase I/II study (NCT01495598), which demonstrated that pomalidomide is well tolerated and has clinical activity in patients with Kaposi sarcoma regardless of HIV status … (leggi tutto)